Edited by Micheal Kalos, Ignacio Melero, and Laszlo Radvanyi
This series is the culmination of a special call for papers that was conducted in early 2018. These original research articles add to the journal’s scope by addressing basic biophysical properties, synthesis and manufacturing, novel mechanisms of action, preclinical safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and regulatory information on new immunotherapy agents and their combinations. They focus on new agents that are intended to begin, or are undergoing, clinical development, while also including molecules that are in advanced clinical development or approved.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com